PA21

Phase 3Completed
1 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemodialysis

Conditions

Hemodialysis, Hyperphosphatemia

Trial Timeline

Apr 29, 2013 → Dec 3, 2013

About PA21

PA21 is a phase 3 stage product being developed by Kissei Pharmaceutical for Hemodialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT01850641. Target conditions include Hemodialysis, Hyperphosphatemia.

What happened to similar drugs?

2 of 15 similar drugs in Hemodialysis were approved

Approved (2) Terminated (0) Active (13)
🔄R744 + R744Chugai PharmaceuticalPhase 3
🔄R744Chugai PharmaceuticalPhase 3
🔄roxadustatAstellas PharmaPhase 3
🔄roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
🔄roxadustatAstellas PharmaPhase 3
DoravirineMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01852682Phase 3Completed
NCT01850641Phase 3Completed
NCT01833494Phase 3Completed

Competing Products

20 competing products in Hemodialysis

See all competitors
ProductCompanyStageHype Score
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744Chugai PharmaceuticalPhase 3
40
roxadustatAstellas PharmaPhase 3
40
ASP7991Astellas PharmaPhase 1
29
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
ASP1585Astellas PharmaPhase 2
35
Kiklin capsulesAstellas PharmaPre-clinical
26
DoravirineMerckApproved
43
BPS804 + PlaceboNovartisPhase 2
27
PA21 + Sevelamer hydrochlorideKissei PharmaceuticalPhase 3
40
PA21 + PA21 + PA21 + PA21 + PlaceboKissei PharmaceuticalPhase 2
35
PA21Kissei PharmaceuticalPhase 3
40
[¹⁴C]EtelcalcetideAmgenPhase 1
29
Epoetin HospiraPfizerPhase 3
40
Epoetin HospiraPfizerPhase 3
40
sodium thiosulfateSanofiPre-clinical
26
EnoxaparineSanofiApproved
43
Alirocumab 150 MG/ML [Praluent]Regeneron PharmaceuticalsPhase 3
36